Ipilimumab/nivolumabLack of efficacy and autoimmune colitis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2035卷 / 1期

关键词：

D O I：

10.1007/s40278-024-71002-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：252 / 252

相关论文

共 50 条

[31] Dacarbazine/ipilimumab/nivolumabLack of efficacy and seronegative encephalitis: case report
Reactions Weekly, 2023, 1955 (1) : 147 - 147
[32] Ipilimumab/NivolumabLack of efficacy and off label use : case report
Reactions Weekly, 2024, 2019 (1) : 229 - 229
[33] Ipilimumab/nivolumab/pembrolizumabMicroscopic colitis: 2 case reports
Reactions Weekly, 2019, 1754 (1) : 204 - 204
[34] NivolumabLack of efficacy and moderate/severe liver rejection: 2 case reports
Reactions Weekly, 2022, 1929 (1) : 504 - 504
[35] Axitinib/dexamethasone/nivolumabLack of efficacy and interstitial pneumonia: 2 case reports
Reactions Weekly, 2023, 1977 (1) : 61 - 61
[36] Ipilimumab/nivolumabLack of efficacy following off label use : case report
Reactions Weekly, 2024, 2031 (1) : 208 - 208
[37] Ipilimumab/nivolumabDiabetes and lack of efficacy: 2 case reports
Reactions Weekly, 2023, 1958 (1) : 288 - 288
[38] NivolumabLack of efficacy, skin rash and elevation of liver enzymes: 2 case reports
Reactions Weekly, 2022, 1892 (1) : 183 - 183
[39] Axicabtagene-ciloleucel/nivolumabLack of efficacy: 7 case reports
Reactions Weekly, 2023, 1974 (1) : 68 - 68
[40] Dacarbazine/ipilimumab/nivolumabElevated liver enzyme levels, autoimmune colitis and hepatotoxicity: 4 case reports
Reactions Weekly, 2019, 1734 (1) : 168 - 168

← 1 2 3 4 5 →